Zacks Investment Research
24 Feb 2026, 01:26 UTC · 35w ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates
Impact · against what's priced in
TARS shows strong commercial scaling with a revenue beat and significant year-over-year growth, though a marginal EPS miss persists. Given the stock's 18.7% year-to-date decline, the market has likely already priced in the company's path to profitability, making this slight earnings miss a negligible factor against strong top-line momentum.
- TARS+0.10
No priced-in read yet
- In context
Revenue grew significantly to $151.67 million from $66.41 million a year ago, beating estimates by 4.63%, which suggests strong commercial execution despite a marginal EPS miss of $0.20 versus the $0.19 expected.
Read from the article alone
Top 1 mover · tap to explore
